2. Signaling Pathways
  3. GPCR/G Protein
    MAPK/ERK Pathway
  4. Ras

Ras

Ras

Related Products

PDF 2.6 MB

Ras is the name given to a family of related proteins which is ubiquitously expressed in all cell lineages and organs. All Ras protein family members belong to a class of protein called small GTPase, and are involved in transmitting signals within cells. Ras is the prototypical member of the Ras superfamily of proteins, which are all related in 3D structure and regulate diverse cell behaviours. When Ras is 'switched on' by incoming signals, it subsequently switches on other proteins, which ultimately turn on genes involved in cell growth, differentiation and survival. As a result, mutations in ras genes can lead to the production of permanently activated Ras proteins. This can cause unintended and overactive signalling inside the cell, even in the absence of incoming signals. Because these signals result in cell growth and division, overactive Ras signaling can ultimately lead to cancer. The 3 Ras genes in humans (HRAS,KRAS, and NRAS) are the most common oncogenes in human cancer; Ras inhibitors are being studied as a treatment for cancer, and other diseases with Ras overexpression.

Ras Isoform Specific Products:

Ras Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-164315
    KRAS G12C inhibitor 67
    		Inhibitor 98.80%
    KRAS G12C inhibitor 67 (example 35) is a KRAS G12C inhibitor that selectively inhibits the growth of many KRAS G12C mutant tumor cell lines.
    KRAS G12C inhibitor 67
  • HY-157029S
    KRASG12D-IN-1
    		Inhibitor 98.07%
    KRASG12D-IN-1 (compound 22) is a KRASG12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition.
    KRASG12D-IN-1
  • HY-151517
    SOS1-IN-14
    		Inhibitor 99.60%
    SOS1-IN-14 is a potent, selective and orally active SOS1 inhibitor with an IC50 value of 3.9 nM. SOS1-IN-14 can be absorbed in the intestine via a P-glycoprotein-mediated efflux mechanism. SOS1-IN-14 can be used to research KRAS-mutated cancers. SOS1-IN-14 has better potent tumor suppression than BI-3406 (HY-125817).
    SOS1-IN-14
  • HY-128590
    PHT-7.3
    		Inhibitor 99.29%
    PHT-7.3 is a selective inhibitor of connector enhancer of kinase suppressor of Ras 1 (Cnk1) pleckstrin homology (PH) domain (Kd=4.7 μM). PHT-7.3 inhibits mut-KRas, but not wild-type KRas cancer cell and tumor growth and signaling. PHT-7.3 has antitumor activity.
    PHT-7.3
  • HY-128771
    K-Ras G12C-IN-4
    		Inhibitor 99.19%
    K-Ras G12C-IN-4, compound 1, is a potent Covalent Inhibitor of KRASG12C.
    K-Ras G12C-IN-4
  • HY-144962
    SOS1-IN-11
    		Inhibitor 98.22%
    SOS1-IN-11 is a potent SOS1 inhibitor with an IC50 value of 30 nM.
    SOS1-IN-11
  • HY-163299
    pan-KRAS-IN-5
    		Inhibitor
    pan-KRAS-IN-5 is a pan-KRAS translation inhibitor by targeting 5′-UTR RNA G-quadruplexes (rG4s). pan-KRAS-IN-5 strongly binds to and stabilizes KRAS rG4s, inhibits KRAS translation, and blocks the MAPK and PI3K-AKT pathways. pan-KRAS-IN-5 induces cell cycle arrest, prompts apoptosis in KRAS-driven cancer cells. pan-KRAS-IN-5 inhibits tumor growth and KRAS expression in KRAS-mutant xenograft. KRAS-IN-5 can be used for KRAS-driven cancer research.
    pan-KRAS-IN-5
  • HY-176523
    KRAS G12D-IN-29
    		Inhibitor
    KRAS G12D inhibitor 29 (Compound Formula (I)) is an orally active and selective KRASG12D mutant inhibitor. KRAS G12D inhibitor 29 blocks downstream signaling pathways mediated by KRASG12D, suppressing tumor cell proliferation. KRAS G12D inhibitor 29 is promising for research of KRASG12D mutation-related cancers (such as pancreatic cancer, lung cancer, colorectal cancer).
    KRAS G12D-IN-29
  • HY-163594
    Pan-RAS-IN-3
    		Inhibitor 99.66%
    Pan-RAS-IN-3 is a pan-Ras inhibitor, and can be used for study of melanoma and acute myeloid leukaemia.
    Pan-RAS-IN-3
  • HY-168054
    PROTAC K-Ras Degrader-3
    		Degrader 98.08%
    PROTAC K-Ras Degrader-3 (compound 40) is a PROTAC degrader of K-Ras with a DC50 of ≤ 1 nM against SW620 KRAS G12D, and a GI50 of ≤ 10 nM against SW620 3D cell growth. PROTAC K-Ras Degrader-3 can be utilized in cancer research.
    PROTAC K-Ras Degrader-3
  • HY-161235
    BTX-7312
    		Degrader 98.35%
    BTX-7312 is a cereblon-based SOS1 bifunctional degrader and a molecular glue. BTX-7312 reduces downstream signaling markers pERK and pS6 and shows antiproliferative activity in various KRAS-mutated cells.
    BTX-7312
  • HY-159652
    KRAS inhibitor-31
    		Inhibitor 99.36%
    KRAS inhibitor-31 (compound 33) is a KRAS inhibitor, with KD (SPR) values of 0.019 nM, 0.019 nM and 0.096 nM for KRas G12D, KRas G12C and KRas G12V, respectively.
    KRAS inhibitor-31
  • HY-163595
    KRAS G12D-IN-31
    		Inhibitor 98.53%
    KRAS G12D-IN-31 is a potent KRAS G12D inhibitor with an IC50 of < 100 nM. KRAS G12D-IN-31 inhibits the proliferation of RAS-dependent cells (KRASG12C, KRAS G12D, KRASG12V and KRASWT). KRAS G12D-IN-31 can be used to study non-small cell lung cancer, gastric cancer, colon cancer, and malignant melanoma.
    KRAS G12D-IN-31
  • HY-115880A
    KRAS G12D inhibitor 3 TFA
    		Inhibitor 98.18%
    KRAS G12D inhibitor 3 TFA is a KRAS G12D inhibitor with an IC50 of <500 nM. KRAS G12D inhibitor 3 TFA has antitumor effects (WO2022002102A1; compound 146). KRAS G12D inhibitor 3 (TFA) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    KRAS G12D inhibitor 3 TFA
  • HY-162960
    pan-KRAS degrader 1
    		Degrader 99.93%
    pan-KRAS degrader 1 (Compound 1) is a panKRAS degrader with a surface plasmon resonance (SPR) dissociation constant Ki value of 25 nM for KRASG12V .pan-KRAS degrader 1 has antitumor activity.
    pan-KRAS degrader 1
  • HY-111550
    Bragsin2
    		Inhibitor 99.85%
    Bragsin2 is a potent, selective and noncompetitive nucleotide exchange factor BRAG2 inhibitor, with an IC50 of 3 μM. Bragsin2 binds at the interface between the PH domain of BRAG2 and the lipid bilayer, leads BRAG2 unable to activate lipidated Arf GTPase. Bragsin2 affects breast cancer stem cells.
    Bragsin2
  • HY-124808
    IMM-01
    		Agonist 99.87%
    IMM-01 is a mammalian Diaphanous (mDia)-related formins agonist that inhibits DID-DAD (diaphanous inhibitory domain-diaphanous autoregulatory domain) binding with an IC50 of 140 nM. IMM-01 acts by disrupting the autoinhibitory bond between the DID and DAD domain and thus activates formins. IMM-01 shows anticancer effects.
    IMM-01
  • HY-101796
    NSC-70220
    		Inhibitor 99.42%
    NSC-70220 is a selective and allosteric SOS1 inhibitor. NSC-70220 inhibits allosteric site activation, and partially inhibited catalytic site activation. NSC-70220 has an anticancer effect.
    NSC-70220
  • HY-172581
    Clifutinib
    		Inhibitor 99.59%
    Clifutinib is an orally active and selective internal tandem duplication mutation of FMS-like tyrosine kinase 3 (FLT3-ITD) inhibitor with an IC50 value of 15.1 nM. Clifutinib exerts strong antiproliferative effects on FLT3-ITD acute myeloid leukemia (AML) cell lines (MV-4-11: IC50 = 1.5 nM; MOLM-13: IC50 = 1.4 nM). Clifutinib inhibits the activity of FLT3-ITD kinase and blocks the downstream RAS/MAPK, PI3K/AKT, and JAK/STAT5 signaling pathways of FLT3. Clifutinib induces apoptosis of acute myeloid leukemia (AML) cells with FLT3-ITD mutations. Clifutinib demonstrates significant antitumor efficacy in mice bearing MV-4-11 or MOLM-13 xenografts. Clifutinib is promising for research of relapsed/refractory FLT3-ITD-positive acute myeloid leukemia.
    Clifutinib
  • HY-170428
    IPS-06061
    		Degrader
    IPS-06061 is an orally active molecule glue, that forms a ternary complex of CRBN-KRASG12D-IPS06061, and degrades KRAS G12D with a DC50 <500 nM.
    IPS-06061
Cat. No. Product Name / Synonyms Application Reactivity
Ras Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.